INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 55 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $30,697,000 | +83.9% | 2,034,263 | +85.7% | 0.01% | +100.0% |
| Q3 2016 | $16,691,000 | -58.8% | 1,095,218 | +5.0% | 0.00% | -66.7% |
| Q2 2016 | $40,493,000 | +50.0% | 1,043,100 | +7.4% | 0.01% | +50.0% |
| Q1 2016 | $26,992,000 | -47.0% | 970,940 | +2.6% | 0.01% | -50.0% |
| Q4 2015 | $50,910,000 | +43.4% | 946,458 | +6.7% | 0.01% | +33.3% |
| Q3 2015 | $35,507,000 | +12.1% | 886,797 | -10.6% | 0.01% | +12.5% |
| Q2 2015 | $31,688,000 | +35.8% | 991,786 | +1.5% | 0.01% | +33.3% |
| Q1 2015 | $23,329,000 | +176.1% | 976,946 | +104.1% | 0.01% | +200.0% |
| Q4 2014 | $8,450,000 | +52.1% | 478,734 | +18.1% | 0.00% | 0.0% |
| Q3 2014 | $5,557,000 | -21.9% | 405,346 | -3.9% | 0.00% | 0.0% |
| Q2 2014 | $7,115,000 | – | 421,993 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |